Skip to main content
. Author manuscript; available in PMC: 2023 Feb 15.
Published in final edited form as: Cancer. 2021 Oct 13;128(4):788–796. doi: 10.1002/cncr.33974

FIGURE 2.

FIGURE 2.

Cumulative mortality (with shaded 95% confidence intervals) from second cancers among patients treated on randomized clinical trials of dexrazoxane (P9404, 9425, 9426, and DFCI 95–01) by dexrazoxane (DRZ) status. Numbers at risk for mortality shown in Figure 1.